• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

Introduction to 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine (CAS No. 459872-41-4)

3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine, identified by the Chemical Abstracts Service Number (CAS No.) 459872-41-4, is a fluorinated aromatic amine that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound, featuring a 3,4-difluorophenyl substituent and a methylpropan-1-amine side chain, exhibits unique structural and electronic properties that make it a promising candidate for various biological and chemical applications.

The structural motif of 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine combines the rigidity of the aromatic ring system with the flexibility of the aliphatic amine group. The presence of fluorine atoms at the 3 and 4 positions introduces electron-withdrawing effects, which can modulate the reactivity and binding affinity of the molecule. This feature is particularly relevant in drug design, where fluorine substitution is often employed to enhance metabolic stability, improve bioavailability, and alter pharmacokinetic profiles.

In recent years, there has been a surge in research focused on fluorinated amines due to their diverse biological activities. Compounds with similar structural scaffolds have been investigated for their potential in treating neurological disorders, infectious diseases, and cancer. The 3,4-difluorophenyl moiety in 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine suggests that it may interact with biological targets in ways that could be exploited for therapeutic purposes. For instance, such molecules have been explored as inhibitors or modulators of enzyme activity, where the fluorine atoms can influence binding interactions at the active site.

One of the most compelling aspects of this compound is its potential as a building block for more complex pharmacophores. The combination of an aromatic ring with electron-deficient fluorine atoms and an amine group capable of hydrogen bonding provides multiple interaction points with biological targets. This versatility has led to its incorporation in several high-throughput screening campaigns aimed at identifying novel bioactive compounds. Researchers have leveraged its structural features to develop derivatives with enhanced potency and selectivity.

The synthesis of 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine involves multi-step organic transformations that highlight the challenges and opportunities in fluorinated chemistry. Key steps typically include the introduction of fluorine atoms into the aromatic ring followed by functionalization at the amine position. Advances in synthetic methodologies have enabled more efficient and scalable production of such compounds, facilitating their use in both academic research and industrial applications.

From a computational chemistry perspective, the electronic properties of 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine have been extensively studied using density functional theory (DFT) and other quantum mechanical methods. These studies reveal that the presence of fluorine atoms significantly alters the electron density distribution around the molecule, influencing its reactivity and interactions with biological systems. Such insights are crucial for rational drug design, allowing chemists to predict and optimize molecular properties before experimental validation.

In clinical research, analogs of 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine have been evaluated for their potential therapeutic effects. Preclinical studies suggest that compounds with similar structural features may exhibit anti-inflammatory, antiviral, or anticancer activities. The exact mechanisms by which these effects are mediated often depend on specific interactions with target proteins or enzymes. For example, some derivatives have shown promise as kinase inhibitors by binding to ATP pockets or as modulators of G-protein coupled receptors (GPCRs).

The pharmaceutical industry has also recognized the value of fluorinated amines in drug development. Their ability to improve pharmacokinetic profiles while maintaining or enhancing biological activity makes them attractive candidates for lead optimization. Companies specializing in medicinal chemistry frequently incorporate such motifs into their libraries to screen for new drug candidates across multiple therapeutic areas.

Environmental considerations are another important aspect when evaluating compounds like 3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine. While fluorinated molecules offer numerous advantages from a chemical standpoint, their environmental fate must be carefully assessed during development. Research into sustainable synthetic routes and biodegradability is ongoing to ensure that these compounds can be utilized responsibly without undue environmental impact.

Future directions in research on this compound may include exploring its role in drug discovery through structure-based design or fragment-based approaches. By understanding how small changes in its structure affect its biological activity, scientists can develop more refined libraries for screening purposes. Additionally, advances in biocatalysis may enable greener synthetic routes to produce analogs on an industrial scale.

In conclusion,3-(3,4-Difluorophenyl)-N-Methylpropan-1-amine (CAS No. 459872-41-4) represents a fascinating example of how structural modifications can yield compounds with significant biological potential. Its unique combination of electronic features and functional groups makes it a valuable tool for researchers investigating new therapeutic strategies across various disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)